Journal
EXPERT REVIEW OF VACCINES
Volume 13, Issue 5, Pages 609-618Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.2014.897617
Keywords
clinical trial; safety; efficacy; hand, foot and mouth disease; seroprevalences; EV71 vaccine; vaccine strain; immunogenicity
Categories
Funding
- China's 12-5 National Major Infectious Disease Program [2012ZX10004703]
Ask authors/readers for more resources
The widespread epidemics of enterovirus 71 (EV71) seriously affected the Western Pacific Region. Young children, especially those younger than 3 years are the most susceptible population to the EV71-associated diseases. Several Asian countries have begun to focus on the research and development of EV71 vaccines. Five inactivated whole-virus EV71 candidate vaccines (three were manufactured in mainland China based on a C4 genotype strain, one in Taiwan based on a B4 genotype strain and one in Singapore based on a B2 genotype strain) have been assessed in clinical trials. Three candidate vaccines developed in mainland China have already completed Phase III clinical trials recently. The tested EV71 vaccine could provide good efficacy, satisfactory safety, and high immunogenicity. Thus, inactivated EV71 vaccines are expected to become the first available vaccines against EV71 in the near future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available